No Data
Stocks that moved the previous day part2 Money Forward, Dai Communications, Bank of Inove, etc.
Stock name <code> 22nd closing price ⇒ previous day comparison Peptide Dream <4587> 2842.5 -125.5 Stock price reaching the 3000 yen range also enhances the sense of achievement. Rakuten Bank <5838> 3110 -165 On the 22nd, bank stocks also experienced almost universal declines. Fujitsu General <6755> 1959.5 -80.5 Earnings reports approaching etc are also seen as cautionary factors. MonotaRO <3064> 2354 -103.5 Strong movements on the 21st due to movements such as raising the target stock price.
Insider decrases its stake in Carna Biosciences(4572.JP) to 3.33%
On Oct 21, モルガン・スタンレー・アンド・カンパニー・インターナショナル・ピーエルシー and related parties submitted the Change Report to Ministry of Finance. The report shows that モルガン・スタンレー・アンド・カンパニー・インターナショナル・ピーエルシー and
Insider holds 7.33% of shares in Carna Biosciences(4572.JP)
On Oct 21, Athos Capital Limited submitted the Large Shareholding Report to Ministry of Finance to disclose its 7.33% ownership of the shares in $Carna Biosciences(4572.JP)$. Source: Edinet
Insider holds 5.53% of shares in Carna Biosciences(4572.JP)
On Oct 4, モルガン・スタンレー・アンド・カンパニー・インターナショナル・ピーエルシー submitted the Large Shareholding Report to Ministry of Finance to disclose its 5.53% ownership of the shares in $Carna Biosciences(4572.JP)$.
Despite softness and the rise in long-term US interest rates, the lower levels appear to be holding firm.
[Emerging Markets Individual Stock Strategy] Today, a soft tone is expected in the emerging markets. In the U.S. stock market on the 25th, the Dow Jones Industrial Average fell by 293.47 points (-0.70%) to 41,914.75, ending a five-day decline. The Dow had been hitting record highs for consecutive days until the previous day, leading to profit-taking sell-offs, and the August new home sales decline from July weighed on stock prices. The Nasdaq was weighed down by the rise in long-term interest rates, but the semiconductor sector was strong, supporting the downside and closing trading slightly higher.
Noil Immun, Carna Bio, and others.
Special profit from the sale of stocks of affiliated companies <3908> expected to be included as special profit at 0.064 billion yen <4572> Issuance of new shares through third-party allocation (1,05600 shares) <4892> Subsidy income from Saifuze of approximately 0.1.4 billion yen expected to be included as non-operating income <4893> Business alliance with Takarabio <4974> in the development of Noil Immune NIB103 <7776> Expected delay in the start date of Cell Seed's homogeneous cartilage cell sheet (CLS2901C) clinical trial
No Data
No Data